AGTC - Applied Genetic Technologies Corporation
| Previous Close | 3.6800 |
| Open | 3.7600 |
| Bid | 3.6600 x 1100 |
| Ask | 6.0000 x 1000 |
| Day's Range | 3.7500 - 4.0900 |
| 52 Week Range | 2.2600 - 7.5000 |
| Volume | 55,391 |
| Avg. Volume | 80,563 |
| Market Cap | 71.958M |
| Beta (3Y Monthly) | 4.30 |
| PE Ratio (TTM) | 42.13 |
| EPS (TTM) | 0.0940 |
| Earnings Date | Feb 6, 2018 - Feb 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.60 |
- Zacks•2 days ago
Agenus' (AGEN) Pipeline Progression on Track Amid Competition
Agenus (AGEN) is developing its pipeline candidates and has an array of collaboration contracts to its credit that bodes well for growth.
- Zacks•3 days ago
Affimed (AFMD) Earnings and Sales Exceed Estimates in Q1
Affimed (AFMD) exceeds earnings and sales estimates in the first quarter of 2019. The company also plans to focus its research and development investments.
- Zacks•6 days ago
Dr. Reddy's (RDY) Q4 Earnings Up Y/Y, Revenues Top Estimates
Dr. Reddy's (RDY) fourth-quarter earnings and sales increase year over year.
- Thomson Reuters StreetEvents•6 days ago
Edited Transcript of AGTC earnings conference call or presentation 7-May-19 12:00pm GMT
Q3 2019 Applied Genetic Technologies Corp Earnings Call
- Zacks•19 days ago
Applied Genetic Technologies (AGTC) Q3 Earnings and Revenues Surpass Estimates
Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of 216.67% and 4163.60%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•19 days ago
Applied Genetic Technologies: Fiscal 3Q Earnings Snapshot
On a per-share basis, the Alachua, Florida-based company said it had net income of 63 cents. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
- GlobeNewswire•19 days ago
AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2019
GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 07, 2019 -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of.
- GlobeNewswire•26 days ago
AGTC to Host Third Quarter Financial Results Conference Call and Webcast on May 7, 2019
GAINESVILLE, Fla. and CAMBRIDGE, Mass., April 30, 2019 -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of.
- Zacks•2 months ago
Applied Genetic Technologies (AGTC) Upgraded to Strong Buy: What Does It Mean for the Stock?
Applied Genetic Technologies (AGTC) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- GlobeNewswire•2 months ago
AGTC Announces Reaching Enrollment Milestones in Phase 1/2 Clinical Trials
Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it has achieved enrollment milestones in two of its Phase 1/2 clinical trials. The company completed enrollment of the dose escalation portion of the achromatopsia (ACHM) CNGB3 trial, which is evaluating the safety and efficacy of its product candidate (rAAV2tYF-PR1.7-hCNGB3) for the treatment of ACHM caused by mutations in the CNGB3 gene.
- Simply Wall St.•2 months ago
What Kind Of Investor Owns Most Of Applied Genetic Technologies Corporation (NASDAQ:AGTC)?
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! A look at the shareholders of Applied Genetic Technologies Corporation (NASDAQ:AGTC) can tell us which group is most powerful...
- MoneyShow•3 months ago
Applied Genetic Technologies- An Eye on Optogenetics
Applied Genetic Technologies (AGTC) is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases, explains Bill Mathews, small cap expert and editor of The Cheap Investor.
- Zacks•3 months ago
Will Applied Genetic Technologies Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Applied Genetic.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of AGTC earnings conference call or presentation 7-Feb-19 1:00pm GMT
Q2 2019 Applied Genetic Technologies Corp Earnings Call
- Associated Press•4 months ago
Applied Genetic Technologies: Fiscal 2Q Earnings Snapshot
On a per-share basis, the Alachua, Florida-based company said it had a loss of 23 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
- GlobeNewswire•4 months ago
AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2018
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Feb. 07, 2019 -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of.
- Zacks•4 months ago
Analysts Estimate Applied Genetic Technologies (AGTC) to Report a Decline in Earnings: What to Look Out for
Applied Genetic Technologies (AGTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•5 months ago
New Research: Key Drivers of Growth for Hewlett Packard Enterprise, Micron Technology, Cirrus Logic, Applied Genetic Technologies, KemPharm, and Communications — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Jan. 02, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Simply Wall St.•5 months ago
Applied Genetic Technologies Corporation (NASDAQ:AGTC): Time For A Financial Health Check
The direct benefit for Applied Genetic Technologies Corporation (NASDAQ:AGTC), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the Read More...
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of AGTC earnings conference call or presentation 8-Nov-18 1:00pm GMT
Q1 2019 Applied Genetic Technologies Corp Earnings Call
Zacks•5 months agoApplied Genetic Technologies Enters Oversold Territory
Applied Genetic Technologies has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
- Benzinga•5 months ago
Sell-Side Roundup: What's Next For For Applied Genetic After 50% Plunge?
Applied Genetic Technologies Corp (NASDAQ: AGTC ), a biotech focused on adeno-associated virus-based gene therapies for the treatment of rare diseases, reported disappointing results from an X-linked retinoschisis ...
- Benzinga•5 months ago
The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen
Here's a roundup of top developments in the biotech space over the last 24 hours. No biotech stock hit 52-week high in Wednesday's session. Down In The Dumps (Biotech stocks hitting 52-week lows on Dec. ...
- ACCESSWIRE•5 months ago
Today's Research Reports on Trending Tickers: Novavax and Applied Genetic Technologies
NEW YORK, NY / ACCESSWIRE / December 13, 2018 / U.S. equities closed higher on Wednesday amidst renewed hopes over the U.S.-China trade talks. According to a report in Wall Street Journal, China is working ...
- GlobeNewswire•5 months ago
AGTC Announces Topline Interim Six-Month Data from Phase 1/2 X-Linked Retinoschisis Clinical Study; Termination of Biogen Collaboration
- Results from XLRS study support general safety and tolerability of AGTC’s gene delivery platform but did not demonstrate signs of clinical activity at interim six-month time.
